Use of chrysophanic acid in inhibiting vascularization

An angiogenesis and rhein technology, applied in the field of compounds, can solve the problems of unclear anti-cancer mechanism and limited anti-cancer effect, and achieve the effects of less drug resistance, high curative effect and small dose

Inactive Publication Date: 2007-06-20
PEKING UNIV FIRST HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional Chinese medicine has used rhubarb in the treatment of cancer, but its anti-cancer mechanism is still unclear, which limits its anti-cancer effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of chrysophanic acid in inhibiting vascularization
  • Use of chrysophanic acid in inhibiting vascularization
  • Use of chrysophanic acid in inhibiting vascularization

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: The inhibitory effect of rhein on the proliferation of human vascular endothelial cells.

[0019] Human umbilical vein endothelial cells (HUVEC, purchased from Cascade Biologics, Cot: C-003-5C) were cultured in Medium 200 (purchased from Cascade Biologics) containing 10% fetal bovine serum (FBS) (37°C, 5 %CO 2 , 95% humidity), the fourth-generation cells were inoculated in a 96-well culture plate at a density of 4000 / 250ul, and a control group, a drug group with various concentration gradients and a blank control were set, and 3 replicate holes were made in each group. When the cell growth density reaches 80%, add 5ul of rhein (dissolved in DMSO) with different concentration gradients respectively, so that the final concentrations are respectively 1000uM, 100uM, 10uM, 5uM and 1uM, add 5ulDMSO to the control group, and continue to cultivate (M200 medium, 2% FBS) 48 hours later, add 5mg / ml tetrazolium bromide (MTT) 20ul, continue to incubate at 37°C for 4 hour...

Embodiment 2

[0020] Example 2: Inhibitory effect of rhein on tube formation ability of human vascular endothelial cells.

[0021] Add BD Matrigel to each well of a 24-well culture plate TM Matrix original glue 200ul, make it polymerized into gel, the fourth generation human umbilical vein endothelial cell (HUVEC) suspension was inoculated into the 24-well plate coated with Matrigel glue at a density of 30000cell / 500ul, set the control group, each concentration gradient In the drug group, 10ul of rhein with a concentration gradient (respectively 1uM, 10uM, 100uM, 1000uM, dissolved in DMSO) was added to the drug group, and 10ul of sterile DMSO was added to the control group, and 3 replicate holes were made in each group. 37°C, 5% CO 2 , 95% humidity for 24 hours, OLYMPUS CK40-RFL optical microscope to observe the formation of vascular endothelial cell tubes, take 4 low-power fields from each well and count them, and take pictures with an OLYMPUS CK40 digital camera. The results are shown ...

Embodiment 3

[0022] Example 3: The inhibitory effect of rhein on the migration ability of human vascular endothelial cells.

[0023] 1. Preparation of chemokines

[0024] The NIH3T3 cells that grew well the next day after passage were used. Gently rinse with serum-free DMEM twice. Serum-free DMEM, 5% CO 2 , 37°C for 24-48 hours. Collect the cell supernatant. Centrifuge (12000g, 4°C, 10min). Filter the supernatant (0.22um filter membrane) and store in aliquots (-20°C).

[0025] 2. Matrigel invasion test

[0026] Take 25ul of diluted Matrigel (the original glue was diluted with DMEM at a ratio of 1:2) and add it to the chamber on the Transwell plate to cover the entire surface of the polyester film, and incubate at 37°C for 30min to make Matrigel polymerize into a gel. The fourth-generation human umbilical vein endothelial cell (HUVEC) suspension was inoculated into the upper chamber at a density of 30000 / 250ul, washed 3 times with PBS, digested and harvested from the culture flask. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses the new use of chrysophanic acid in inhibiting vasculariztion. Research probes the vasculariztion inhibiting effect of chrysophanic acid. The technological scheme is that chrysophanic acid is used in preparing medicine for prevention and / or treatment of inhibiting vasculariztion with the dosage being 0.5-3.0 mg / kg body weight / day. The present invention uses the vasculariztion as the target of treating diseases and has the advantages of treatment specificity of pointing newly formed vessel; small dosage, high treating effect and less side effect owing to the direct action of medicine to vascular endothelial cell; and less medicine resistance owing to relatively stable endothelial cell gene expression.

Description

technical field [0001] The present invention relates to a new application of the compound, in particular to a new application of rhein. Background technique [0002] Studies have shown that tumors themselves have the ability to initiate and promote angiogenesis to meet their own metabolism and nutrient supply needs. Tumor angiogenesis starts from the existing vascular bed. If there is no angiogenesis, the growth of the primary tumor will not exceed 1-2mm, and there will be no invasion and metastasis. Inhibiting tumor angiogenesis is closely related to blocking tumor occurrence, development, invasion and metastasis. Inhibiting tumor angiogenesis can also prevent the malignant transformation of precancerous lesions into cancer. Not only the growth, invasion and metastasis of solid tumors depend on angiogenesis, but also the growth and metastasis of hematological malignancies (such as malignant lymphoma, lymphocytic leukemia, etc.) are closely related to angiogenesis. Tumor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/192A61P35/00
Inventor 王振军赵博
Owner PEKING UNIV FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products